Skip to main content
search
Category

Regulatory Affairs Working Party Archive

Regulatory Affairs Working PartyRegulatory Affairs Working Party Archive

BIVDA Regulatory Working Party update – 17 December 2021

BIVDA held our Regulatory Affairs working party on Friday 17th December. The meeting provided an update on the ongoing and future regulatory work being conducted within the IVD sector. This was opened by a presentation from Richard Saunders, our chair, on the European situation. Numerous guidance pages have been drafted by MedTech Europe to ease compliance to the IVDR. As…
admin
December 17, 2021
Regulatory Affairs Working PartyRegulatory Affairs Working Party Archive

BIVDA involvement with ongoing MHRA regulatory work

BIVDA takes part in the monthly MHRA/Trade Association meeting which allows for open dialogue between everyone involved. Recently, this has been focussed on the ongoing regulatory changes in the UK. This meeting is BIVDA’s opportunity to raise any concerns from members and get key insight into the regulatory changes in the UK. The last meeting was on 2 December, providing…
admin
December 9, 2021
Regulatory Affairs Working PartyRegulatory Affairs Working Party Archive

European Council confirms they will not amend IVDR delay proposal

On 1st December, the European Council confirmed that they have agreed to proceed with an accelerated legislative procedure for the proposed delay of the EU IVDR. This means they will not be suggesting any changes to the text included with the proposal in order for it to progress through legislation more quickly than would typically take. This proposal pushes back…
admin
December 3, 2021
Consultations ArchiveRegulatory Affairs Working PartyRegulatory Affairs Working Party Archive

Consultation on specific IVD related GMDN terms

The GMDN Agency have provided the summary information below. This is regarding a consultation on specific IVD related GMDN terms. The IVD Team at the GMDN Agency have launched a consultation regarding a proposed scaling back of antibody-specific IVD terms within the GMDN. The move would be to consolidate all infectious disease antibody-class specific terms for a particular analyte to…
admin
November 19, 2021
Regulatory Affairs Working PartyRegulatory Affairs Working Party Archive

Regulatory Affairs information on product registrations with MHRA

As you all know, all general IVDs have to be registered with MHRA by 31st December. We have recently had a number of issues about delays to registration raised by members, frustrated by lack of response from MHRA to email queries. Doris-Ann raised this as an agenda item for the MHRA Liaison meeting yesterday. MHRA’s response was that they are…
admin
November 5, 2021
Regulatory Affairs Working PartyRegulatory Affairs Working Party Archive

Regulatory Affairs Seminar 11 – 13 October 2021

This year’s RAWP Seminar has taken place this week face to face in the wonderful city of Liverpool. Members were able to access key speakers from MedTech Europe and MHRA discussing a wealth of key IVD Regulatory related topics including IVDR timelines, UKCA implementation updates and discussions, new MHRA UK Legislation discussions, DEFRA, HSE and impact analysis.  They were also…
admin
October 14, 2021
Close Menu